How artificial intelligence enables modeling and simulation of biological networks to accelerate drug discovery
Author:
Open Access
- 4 October 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Drug Discovery
- Vol. 2
Abstract
The pharmaceutical industry suffered a significant decline of innovation in the last few decades, whose simple reason is complex biology. Artificial intelligence (AI) promises to make the entire drug discovery and development process more efficient. Here I consider the potential benefits of using AI to deepen our mechanistic understanding of disease by leveraging data and knowledge for modeling and simulation of genome-scale biological networks. I outline recent developments that are moving the field forward and I identify several overarching challenges for advancing the state of the art towards the successful integration of AI with modeling and simulation in drug discovery.Keywords
This publication has 122 references indexed in Scilit:
- A Whole-Cell Computational Model Predicts Phenotype from GenotypeCell, 2012
- Unveiling the role of network and systems biology in drug discoveryTrends in Pharmacological Sciences, 2010
- Systems biology of SNPsMolecular Systems Biology, 2006
- Towards multidimensional genome annotationNature Reviews Genetics, 2006
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- Advances in the prediction of protein targeting signalsProteomics, 2004
- Oncology's trialsNature Reviews Drug Discovery, 2003
- Making Better Drugs: Decision Gates in Non-Clinical Drug DevelopmentNature Reviews Drug Discovery, 2003
- In Silico Model-Driven Assessment of the Effects of Single Nucleotide Polymorphisms (SNPs) on Human Red Blood Cell MetabolismGenome Research, 2002
- A NEWAPPROACH TODECODINGLIFE: Systems BiologyAnnual Review of Genomics and Human Genetics, 2001